Clinical Scorecard: Selecting the Appropriate Plasma pTau217 Assay for Clinical Use: Clarifying the Complexities

At a Glance

Key Highlights

• Plasma pTau217 assays show excellent accuracy (AUC 0.91–0.97) for detecting amyloid and tau PET positivity.
• Mass spectrometry-based %pTau217WashU assay outperforms immunoassays and FDA-approved CSF biomarkers in accuracy and is unaffected by kidney function.
• Immunoassays (MSD, SIMOA, NULISA, Lumipulse) offer scalable, cost-effective alternatives with varying performance profiles.

Guideline-Based Recommendations

Diagnosis

• Use plasma pTau217 assays to non-invasively detect amyloid-β and tau pathology in Alzheimer's disease.
• Consider mass spectrometry-based %pTau217WashU assay for highest accuracy if available.
• Immunoassays such as pTau217Lilly and pTau217ALZpath are suitable alternatives where mass spectrometry is not feasible.

Management

• Employ plasma pTau217 biomarkers for patient stratification in clinical trials, especially for tau quantification.
• Prioritize blood-based biomarkers over CSF biomarkers for monitoring disease progression due to better dynamic range.

Monitoring & Follow-up

• Monitor longitudinal changes in amyloid and tau PET burden using plasma pTau217 assays, with %pTau217WashU showing superior predictive ability.
• Be aware that some assays (e.g., pTau217ALZpath) may have limited ability to discriminate tau stages.

Risks

• Mass spectrometry assays require expensive equipment and trained personnel, limiting scalability.
• Some immunoassays (e.g., pTau217Janssen) may have lower accuracy compared to FDA-approved CSF biomarkers.
• CSF pTau181Elecsys assay performs worse than plasma pTau217 assays in most outcomes.

Patient & Prescribing Data

Individuals undergoing evaluation for Alzheimer's disease pathology including cognitively impaired and unimpaired adults

Plasma pTau217 assays provide a non-invasive, cost-effective tool for early diagnosis and monitoring, facilitating timely therapeutic interventions and clinical trial enrollment.

Clinical Best Practices

• Select plasma pTau217 assay based on available laboratory resources balancing accuracy and scalability.
• Use %pTau217WashU assay preferentially when mass spectrometry is accessible for superior diagnostic performance.
• Employ immunoassays like pTau217Lilly or ALZpath for high-throughput clinical screening.
• Interpret plasma pTau217 results in conjunction with imaging and clinical assessments for comprehensive evaluation.
• Consider kidney function influence when selecting biomarkers; %pTau217WashU is unaffected by renal status.

References

• Warmenhoven et al. - Head-to-head comparison of plasma pTau217 assays
• Pilotto et al. - Plasma p-tau217 Lumipulse and ALZpath SIMOA comparison
• NULISA platform biomarker analysis
• Lumipulse platform in Alzheimer's disease research
• Tau quantification importance for clinical trials